Biofluids
Cell-free biofluids such as blood plasma, cerebrospinal fluid (CSF), bile, and saliva contain RNA molecules that have either been secreted by cells in local tissue or transferred from other parts of the body by blood or lymph.
These RNA molecules are emerging as potential biomarkers for a wide range of diseases, as changes in the RNA profile of various biofluids may offer key information for diagnosis, tracking disease progression, and monitoring treatment response.
RNA sequencing is a powerful tool for screening potential RNA biomarkers in biofluids.
Early Diagnostics
Early Diagnostics
Quantification of RNA biomarkers to enable diagnosis at earlier stages and potentially mitigate or delay disease progression
Companion diagnostics
Companion Diagnostics
Tracking central biomarkers along disease progression to monitor and provide optimal treatment for individual patients
Treatment response validation
Treatment response validation
Monitoring RNA biomarker levels to evaluate treatment performance
RNA biomarkers offer several advantages over their protein counterparts:
Cell-free biofluids have ultra-low RNA content. The power of sequencing RNA in biofluids for biomarker screening therefore relies heavily on expert sample preparation and bioinformatics to ensure the highest quality RNA samples and results.
Omiics specializes in ultra-low input samples for RNA NGS, having ample experience with biofluids including plasma, CSF, saliva, bile, etc.
We use optimized protocols for biofluid samples, performed under highly controlled and traceable conditions in our Aarhus-based laboratory. With our meticulous laboratory work, and expert bioinformatic analysis, we can assure high quality and reliable results.
Sample preparation
Sequencing
Data analysis
Read more on our experience with different types of low-input biofluid samples
NGS service provider with a focus on customer needs. We deliver flexible solutions to your specific demands.
Contact us for a non-binding discussion about your next project.
